ClinicalTrials.gg
CompletedNCT06327126Updated Jul 17, 2024

Efficacy and Safety of Single-session Endoscopic Stone Extraction

An observational study in Choledocholithiasis With Acute Cholangitis, sponsored by Beijing Friendship Hospital. Completed at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-07-17.

Sponsored by Beijing Friendship Hospital · Observational

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
563
Ages
18 Years and older
Sex
All
01

Study summary

This is a retrospective study, including approximately 600 patients with acute cholangitis accompanied with choledocholithiasis, who treated with single-session or two-session endoscopic stone extraction at Beijing friendship hospital. The investigators assessed the outcomes of single-stage and two-stage endoscopic stone extraction.

Read the detailed description

Acute cholangitis is an acute inflammation caused by obstruction of the bile duct, of which choledocholithiasis is the most common cause. Without timely removal of the obstruction or control of the infection, cholangitis can get worse and even become life-threatening. Therefore, timely and effective treatment is essential for patients with acute cholangitis combined with choledocholithiasis. Endoscopic retrograde cholangiography (ERCP) is used as the first-line treatment for choledocholithiasis-associated acute cholangitis. Previous guidelines recommended two-session endoscopic therapy. Endoscopic biliary drainage as the initial treatment, followed by endoscopic stone extraction after cholangitis improved. In recent years, studies have found that single-session endoscopic stone extraction is safe and effective for patients without serious organ function impairment. Meanwhile, single-session endoscopic lithotomy can avoid the second ERCP intervention, which can relieve the pain of patients, reduce medical costs and shorten the length of hospital stay. However, there is still insufficient evidence on the effectiveness and safety of early single-session ERCP lithotomy. The aim of this study is to evaluate the efficacy and safety of single-session endoscopic stone extraction for acute cholangitis associated with choledocholithiasis, so as to provide reference of clinical treatment.

In a retrospective analysis, approximately 600 patients with acute cholangitis accompanied with choledocholithiasis, who treated with single-session or two-session endoscopic stone extraction at Beijing friendship hospital were studied. The investigators assessed the outcomes of single-stage and two-stage endoscopic stone extraction.

02

Conditions studied

  • Choledocholithiasis With Acute Cholangitis

Browse trials for

Keywords

  • Choledocholithiasis
  • Acute Cholangitis
  • Endoscopic Retrograde Cholangiopancreatography
03

In context

Choledocholithiasis

109 studies on the registry are indexed under Choledocholithiasis; 24 are open to participants now.

This study's enrollment of 563 is above the median of 200 across 31 observational studies indexed under Choledocholithiasis.

Browse Choledocholithiasis studies →

Lead sponsor

Beijing Friendship Hospital is the lead sponsor of 217 studies on the registry; 94 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients who diagnosed with acute cholangitis associated with choledocholithiasis underwent single-session stone extraction or two-session treatment involving stone removal after drainage at Beijing Friendship Hospital.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥18 years old
  2. Patients met the Tokyo Guidelines 2018 (TG18) diagnosis of acute cholangitis
  3. Imaging examination confirmed the presence of choledocholithiasis
  4. Patients received endoscopic single-session stone extraction or two-session treatment involving stone removal after drainage

Exclusion criteria

Exclusion Criteria:

  1. Common bile duct with benign or malignant stenosis
  2. Changes in the anatomical structure of the stomach or duodenum
  3. Patients complicated with severe acute pancreatitis
  4. Patients who underwent endoscopic intervention before admission
  5. Patients received percutaneous transhepatic cholangio drainage (PTCD) or other invasive interventions besides endoscopic treatment
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
563 participants (actual)
Patient registry
No

Groups and cohorts

  • two-session treatment group

    two-session ERCP

    Procedure: two-session ERCP

  • single-session treatment group

    single-session ERCP

    Procedure: single-session ERCP

Interventions

  • Proceduretwo-session ERCP

    early endoscopic drainage followed by endoscopic stone extraction

  • Proceduresingle-session ERCP

    directly endoscopic stone extraction

06

What researchers measure

Primary outcomes

  1. Success rate of complete stone removal

    Segmental angiography was performed by balloon closure to determine the presence or absence of negative stone shadow

    Time frame: during the operation

  2. ERCP-related complication rate

    The complications include pancreatitis, hemorrhage, perforation, pneumonia, etc. The results of intraoperative endoscopic observation, postoperative symptoms and signs, blood routine examination, amylase, lipase, and imaging and endoscopic examination were measured.

    Time frame: from the operation to 1 month after the operation

Secondary outcomes

  1. Length of stay

    Total time from admission to discharge.

    Time frame: perioperatively

  2. Hospital expenses

    Total expenses from admission to discharge.

    Time frame: perioperatively

07

Study locations

1 site
  • Beijing Friendship Hospital
    Beijing, Beijing 100050, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 17, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06327126
Responsible party
Sponsor
First posted
Mar 25, 2024
Start date
Jan 1, 2024
Primary completion
May 1, 2024
Completion
Jul 1, 2024
Last update
Jul 17, 2024

Study contacts

Fujing Lv, M.D.
principal investigator · Beijing Friendship Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion